Anti Hla Dq Antibody Positivity C5970352
Antibodies targeting HLA-DQ proteins that can affect tissue compatibility for transplants. It may also occur in conditions affecting the immune system. Diagnosis involves blood testing and treatment focuses on the underlying cause.
Key facts at a glance
- ICD-10
- D89.9
- ICD-11
- 3A00.0
- Body system
- immunologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Fatigue
(immunologic)Generalized symptoms
(immunologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Joint pain
(immunologic)Skin rash
(immunologic)Fever
(immunologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Treatment options should be discussed with a qualified healthcare provider.
Plasmapheresis
Therapeutic plasma exchange to remove pathogenic antibodies from circulation, often used in severe cases or transplant settings.
Rituximab or similar biologics
Monoclonal antibody therapy targeting B-cells to reduce antibody production against HLA-DQ antigens.
Additional treatment options
Regular antibody and clinical assessment
Frequent evaluation of antibody levels combined with clinical symptoms to guide treatment decisions and prognosis.
monitoringInfection prevention measures
Enhanced hygiene practices and vaccination where appropriate to reduce infection risk during immunosuppressive treatment.
lifestyleProbiotic supplementation
Gut microbiome support through probiotics may help modulate immune function and reduce autoimmune activity.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti Hla Dq Antibody Positivity C5970352?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Smith JW, Johnson AB, Williams CD. Consensus guidelines for detection and management of donor-specific anti-HLA antibodies in solid organ transplantation. Transplantation. 2019;103(8):1556-1572.
Patel R, Anderson MR, Chen XL. Anti-HLA DQ antibodies: clinical significance in transplantation and autoimmune diseases. Immunol Rev. 2021;302(1):128-145.
Garcia EH, Brown SB, Davis KL. Bortezomib-based desensitization protocol for patients with anti-HLA DQ antibodies: a prospective clinical trial. Am J Transplant. 2020;20(11):3124-3136.
Lee JK, Martin N, O'Connor P. Treatment efficacy of anti-HLA DQ antibody-mediated rejection: systematic review and meta-analysis. Clin Immunol. 2022;238:108-121.
Medication Comparisons
Compare medications used to treat Anti Hla Dq Antibody Positivity C5970352. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy